ASKA has announced the launch of Irinotecan, the first oncology product from Actavis in Japan. This product is the anticancer agent which inhibits the topoisomerase I, and ASKA obtained the marketing approval on 15 July 2011 and the NHI listing on 28 November 2011.

This product is supplied from the Swiss based pharmaceutical company Actavis which is marketing the generic products in oncology field globally and is distributed through Takeda Pharmaceutical Company Limited. Actavis has already launched Irinotecan in more than 35 countries. Irinotecan Actavis is produced by the Company’s Romanian facility, which is approved by the FDA (US), EMEA (EU) and the Japanese regulatory authorities.

By launch of this product, ASKA and Actavis will contribute to the restraining of medical expenses, reducing of patient burden and hospital management. Through this partnership ASKA and Actavis will make the contribution to the treatment in oncology area.

Enquiries

Actavis Group
Frank Staud
EVP Corporate Communication
Tel: +41 79 230 95 78
E-mail: fstaud@actavis.com